PERTH, Australia, June 03, 2024 (GLOBE NEWSWIRE) — Locafy Limited (Nasdaq: LCFY, LCFYW) (“Locafy” or the “Company”), a globally recognized […]
SAN FRANCISCO, June 03, 2024 (GLOBE NEWSWIRE) — Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel […]
REDWOOD CITY, Calif., June 03, 2024 (GLOBE NEWSWIRE) — Biomea Fusion, Inc. (Nasdaq: BMEA) (“Biomea” or the “Company”), a clinical […]
3Q24 revenue grew 6% to $514.2 million. Growth was driven by continued market share gains and volume growth, which mitigated […]
REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), June 3, 2024, 10.05pm CET / 4.05pm [...]
SOUTH SAN FRANCISCO, Calif., June 03, 2024 (GLOBE NEWSWIRE) — Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company […]
FibroGen to evaluate FG-3165, an anti-galectin 9 (Gal9) monoclonal antibody (mAb), as monotherapy treatment as well as in combination with […]
LOS ANGELES, June 03, 2024 (GLOBE NEWSWIRE) — Dave (NASDAQ: DAVE), one of the nation’s leading neobanks, announced an extension […]
First Quarter Fiscal Year 2025 Highlights: Total revenue of $169.2 million, up 33% year-over-year Significant year-over-year GAAP and Non-GAAP operating […]
CAMBRIDGE, Mass., June 03, 2024 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying […]
